{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:09:51Z","timestamp":1790744991628,"version":"4.1.0"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"IMK Fonden"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cell & Developmental Biology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.semcdb.2020.10.006","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T02:41:07Z","timestamp":1604457667000},"page":"49-58","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Multiple myeloma\u2014A painful disease of the bone marrow"],"prefix":"10.1016","volume":"112","author":[{"given":"Marta","family":"Diaz-delCastillo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Chantry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Heegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.semcdb.2020.10.006_bb1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol."},{"issue":"19","key":"10.1016\/j.semcdb.2020.10.006_bb2","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1182\/blood-2008-12-192575","article-title":"Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance","volume":"114","author":"Vachon","year":"2009","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb5","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood-2008-12-191676","article-title":"Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden","volume":"114","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb6","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/j.ejca.2005.11.033","article-title":"Familial risks and temporal incidence trends of multiple myeloma","volume":"42","author":"Altieri","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"25","key":"10.1016\/j.semcdb.2020.10.006_bb7","doi-asserted-by":"crossref","first-page":"6386","DOI":"10.1182\/blood-2009-02-203471","article-title":"Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb8","doi-asserted-by":"crossref","first-page":"215","DOI":"10.5271\/sjweh.782","article-title":"Occupation, pesticide exposure and risk of multiple myeloma","volume":"30","author":"Baris","year":"2004","journal-title":"Scand. J. Work Environ. Health"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1080\/1059924X.2012.632339","article-title":"Multiple myeloma and exposure to pesticides: a Canadian case-control study","volume":"17","author":"Pahwa","year":"2012","journal-title":"J. Agromed."},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1002\/ijc.30218","article-title":"Pesticide exposures and the risk of multiple myeloma in men: an analysis of the North American Pooled Project","volume":"139","author":"Presutti","year":"2016","journal-title":"Int. J. Cancer"},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb11","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ijc.28191","article-title":"Multiple pesticide exposures and the risk of multiple myeloma in Canadian men","volume":"133","author":"Kachuri","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb12","first-page":"565","article-title":"Malignant diseases of hematopoietic and lymphoid tissues in Chernobyl clean-up workers","volume":"5","author":"Gluzman","year":"2005","journal-title":"Hematol. J. Off. J. Eur. Haematol. Assoc."},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb13","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/blood-2008-05-159665","article-title":"Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors","volume":"113","author":"Iwanaga","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12185-011-0971-z","article-title":"Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients","volume":"95","author":"Kaya","year":"2012","journal-title":"Int. J. Hematol."},{"issue":"15","key":"10.1016\/j.semcdb.2020.10.006_bb15","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1200\/JCO.2006.09.0100","article-title":"Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003","volume":"25","author":"Kristinsson","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0208507","article-title":"Real-world treatment outcomes in multiple myeloma: multicenter registry results from Finland 2009-2013","volume":"13","author":"Remes","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.semcdb.2020.10.006_bb17","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4625787","article-title":"Real-world treatment patterns, outcomes, and healthcare resource utilization in relapsed or refractory multiple myeloma: evidence from a medical record review in France","volume":"2019","author":"Lin","year":"2019","journal-title":"Adv. Hematol."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","article-title":"Multiple myeloma: practice patterns across Europe","volume":"175","author":"Raab","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/10428194.2019.1633633","article-title":"Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged \u2265 75 years","volume":"60","author":"Bashir","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb20","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb21","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.semcdb.2020.10.006_bb23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2008","journal-title":"Leukemia"},{"issue":"22","key":"10.1016\/j.semcdb.2020.10.006_bb24","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study","volume":"113","author":"Landgren","year":"2009","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb25","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N. Engl. J. Med."},{"issue":"9727","key":"10.1016\/j.semcdb.2020.10.006_bb26","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/S0140-6736(10)60482-5","article-title":"Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study","volume":"375","author":"Dispenzieri","year":"2010","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.semcdb.2020.10.006_bb27","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcdb.2020.10.006_bb28","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/leu.2014.34","article-title":"Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12\u2009482 persons from the National Health and Nutritional Examination Survey","volume":"28","author":"Landgren","year":"2014","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb29","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb30","doi-asserted-by":"crossref","first-page":"4646","DOI":"10.1182\/blood-2002-01-0148","article-title":"Immunocytochemistry reveals RANKL expression of myeloma cells","volume":"99","author":"Sezer","year":"2002","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb31","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1182\/blood.V96.2.671.014k24_671_675","article-title":"Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma","volume":"96","author":"Choi","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb32","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb33","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb34","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/leu.2015.259","article-title":"Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20","volume":"30","author":"Palma","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.semcdb.2020.10.006_bb35","doi-asserted-by":"crossref","first-page":"6840","DOI":"10.1158\/0008-5472.CAN-08-0402","article-title":"CC-chemokine ligand 20\/macrophage inflammatory protein-3alpha and CC-chemokine receptor 6 are overexpressed in myeloma microenvironment related to osteolytic bone lesions","volume":"68","author":"Giuliani","year":"2008","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.semcdb.2020.10.006_bb36","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.semcdb.2020.10.006_bb37","first-page":"4242","article-title":"Production of interleukin 1 beta, a potent bone resorbing cytokine, by cultured human myeloma cells","volume":"49","author":"Yamamoto","year":"1989","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb38","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(02)00915-8","article-title":"Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism","volume":"32","author":"Kudo","year":"2003","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb40","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1002\/jbmr.210","article-title":"Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts","volume":"26","author":"Danks","year":"2011","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb41","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/leu.2015.228","article-title":"Targeting IL-17A in multiple myeloma: a potential novel therapeutic approach in myeloma","volume":"30","author":"Prabhala","year":"2016","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005275","article-title":"Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone","volume":"4","author":"Mohammad","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.semcdb.2020.10.006_bb43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.bone.2016.07.007","article-title":"Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease","volume":"91","author":"Nyman","year":"2016","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb44","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajpath.2015.11.003","article-title":"Inhibition of transforming growth factor-beta activation diminishes tumor progression and osteolytic bone disease in mouse models of multiple myeloma","volume":"186","author":"Lu","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb45","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J. Clin. Investig."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb46","first-page":"52","article-title":"Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma","volume":"20","author":"Filella","year":"1996","journal-title":"Cancer Detect. Prev."},{"issue":"29","key":"10.1016\/j.semcdb.2020.10.006_bb47","doi-asserted-by":"crossref","first-page":"27343","DOI":"10.18632\/oncotarget.4398","article-title":"Inhibition of miR-21 restores RANKL\/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts","volume":"6","author":"Pitari","year":"2015","journal-title":"Oncotarget"},{"issue":"24","key":"10.1016\/j.semcdb.2020.10.006_bb48","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1182\/blood-2011-07-366633","article-title":"Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma","volume":"119","author":"Mimura","year":"2012","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.semcdb.2020.10.006_bb49","doi-asserted-by":"crossref","first-page":"4205","DOI":"10.1182\/blood-2011-05-353300","article-title":"Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation","volume":"119","author":"Xu","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.semcdb.2020.10.006_bb50","doi-asserted-by":"crossref","first-page":"5903","DOI":"10.1158\/1078-0432.CCR-07-0753","article-title":"Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model","volume":"13","author":"Neri","year":"2007","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb51","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bone.2010.12.023","article-title":"RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II","volume":"48","author":"Hemingway","year":"2011","journal-title":"Bone"},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb52","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood.V91.8.2679.2679_2679_2688","article-title":"Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation","volume":"91","author":"Dhodapkar","year":"1998","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.semcdb.2020.10.006_bb53","doi-asserted-by":"crossref","first-page":"10393","DOI":"10.18632\/oncotarget.2084","article-title":"Notch signaling drives multiple myeloma induced osteoclastogenesis","volume":"5","author":"Colombo","year":"2014","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb54","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.humpath.2010.05.002","article-title":"Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance","volume":"41","author":"Skrtic","year":"2010","journal-title":"Hum. Pathol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2141.2003.04589.x","article-title":"Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications","volume":"123","author":"Saeki","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb56","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1756-8722-4-22","article-title":"Circulating osteopontin: a dual marker of bone destruction and angiogenesis in patients with multiple myeloma","volume":"4","author":"Sfiridaki","year":"2011","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb57","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.semcdb.2020.10.006_bb58","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2008-08-173948","article-title":"Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation","volume":"113","author":"Hiruma","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb59","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1182\/blood-2006-07-035857","article-title":"Mechanisms of regulation of CXCR4\/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma","volume":"109","author":"Alsayed","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb60","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.semcdb.2020.10.006_bb61","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb62","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2014.02.010","article-title":"Bone marrow plasma macrophage inflammatory protein protein-1 alpha(MIP-1 alpha) and sclerostin in multiple myeloma: relationship with bone disease and clinical characteristics","volume":"38","author":"Wang","year":"2014","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcdb.2020.10.006_bb63","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/289458","article-title":"Cellular mechanisms of multiple myeloma bone disease","volume":"2013","author":"Oranger","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb64","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","article-title":"Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease","volume":"107","author":"Vallet","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.semcdb.2020.10.006_bb65","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","article-title":"Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy","volume":"23","author":"Terpos","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb66","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jbmr.2789","article-title":"Regulation of sclerostin expression in multiple myeloma by Dkk-1: a potential therapeutic strategy for myeloma bone disease","volume":"31","author":"Eda","year":"2016","journal-title":"J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res."},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb67","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","article-title":"Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy","volume":"131","author":"Terpos","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb68","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/bmb\/ldu016","article-title":"Myeloma bone disease: pathogenesis, current treatments and future targets","volume":"111","author":"Walker","year":"2014","journal-title":"Br. Med. Bull."},{"issue":"9","key":"10.1016\/j.semcdb.2020.10.006_bb69","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood-2004-12-4940","article-title":"Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2","volume":"106","author":"Oshima","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2020.10.006_bb70","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.0105-2896.2005.00323.x","article-title":"The role of immune cells and inflammatory cytokines in Paget's disease and multiple myeloma","volume":"208","author":"Ehrlich","year":"2005","journal-title":"Immunol. Rev."},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb71","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2013.385","article-title":"Bone marrow monocyte-\/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma","volume":"28","author":"Silbermann","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb72","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1182\/blood-2004-12-4986","article-title":"Myeloma cells block RUNX2\/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation","volume":"106","author":"Giuliani","year":"2005","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.semcdb.2020.10.006_bb73","doi-asserted-by":"crossref","first-page":"6871","DOI":"10.1182\/blood-2011-04-346775","article-title":"Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease","volume":"118","author":"D'Souza","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2020.10.006_bb74","doi-asserted-by":"crossref","first-page":"7644","DOI":"10.1073\/pnas.93.15.7644","article-title":"Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro","volume":"93","author":"Grano","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb75","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","article-title":"HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma","volume":"109","author":"Standal","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcdb.2020.10.006_bb76","article-title":"The role of TGF-\u03b2 in bone metastasis: novel therapeutic perspectives","volume":"1","author":"Buijs","year":"2012","journal-title":"Bone Rep."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb77","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0002-9343(97)80047-2","article-title":"Hypercalcemia of malignancy","volume":"103","author":"Mundy","year":"1997","journal-title":"Am. J. Med."},{"key":"10.1016\/j.semcdb.2020.10.006_bb78","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/ncomms9983","article-title":"Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche","volume":"6","author":"Lawson","year":"2015","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb79","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","article-title":"Multiple myeloma: patient outcomes in real-world practice","volume":"175","author":"Yong","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.semcdb.2020.10.006_bb80","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb81","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00277-016-2835-3","article-title":"Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA\/GEM05 trials","volume":"95","author":"Mateos","year":"2016","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb82","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11899-011-0080-3","article-title":"Treatment of newly diagnosed myeloma in patients not eligible for transplantation","volume":"6","author":"Mateos","year":"2011","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb83","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.clinthera.2018.05.012","article-title":"Cost-effectiveness of daratumumab-based triplet therapies in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Zhang","year":"2018","journal-title":"Clin. Ther."},{"issue":"10","key":"10.1016\/j.semcdb.2020.10.006_bb84","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs. placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Mateos","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcdb.2020.10.006_bb85","first-page":"1095","article-title":"Potential role of daratumumab in the treatment of multiple myeloma","volume":"7","author":"Khagi","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb86","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb87","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1007\/s12325-016-0413-7","article-title":"The role of panobinostat plus bortezomib and dexamethasone in treating relapsed or relapsed and refractory multiple myeloma: a European perspective","volume":"33","author":"San-Miguel","year":"2016","journal-title":"Adv. Ther."},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb88","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb89","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/hon.2688","article-title":"Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing\/progressing after autologous stem cell transplantation","volume":"37","author":"Ikeda","year":"2019","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb90","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1600-0609.2009.01250.x","article-title":"Health related quality of life in a nationally representative sample of haematological patients","volume":"83","author":"Johnsen","year":"2009","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb91","doi-asserted-by":"crossref","DOI":"10.1186\/2052-1839-13-9","article-title":"Time-to-diagnosis and symptoms of myeloma, lymphomas and leukaemias: a report from the Haematological Malignancy Research Network","volume":"13","author":"Howell","year":"2013","journal-title":"BMC Hematol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb92","first-page":"417","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb93","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur. J. Haematol."},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb94","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J. Pain Symptom Manag."},{"issue":"9","key":"10.1016\/j.semcdb.2020.10.006_bb95","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.3390\/cancers11091300","article-title":"Assessing cachexia acutely after autologous stem cell transplant","volume":"11","author":"Anderson","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.semcdb.2020.10.006_bb96","article-title":"Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study","author":"Nielsen","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semcdb.2020.10.006_bb97","first-page":"1","article-title":"Quality of life in patients with relapsed\/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population","author":"Ludwig","year":"2019","journal-title":"Leuk. Lymphoma"},{"issue":"15","key":"10.1016\/j.semcdb.2020.10.006_bb98","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1016\/j.ejca.2007.06.001","article-title":"Quality-of-life in elderly patients with cancer: a short review","volume":"43","author":"Wedding","year":"2007","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb99","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ejh.12882","article-title":"A systematic review of health-related quality of life in longitudinal studies of myeloma patients","volume":"99","author":"Nielsen","year":"2017","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb100","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb101","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1158\/1078-0432.CCR-15-2035","article-title":"Focusing on core patient-reported outcomes in cancer clinical trials: symptomatic adverse events, physical function, and disease-related symptoms","volume":"22","author":"Kluetz","year":"2016","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"issue":"5 Suppl","key":"10.1016\/j.semcdb.2020.10.006_bb102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1188\/17.CJON.S5.47-59","article-title":"Bone health, pain, and mobility: evidence-based recommendations for patients with multiple myeloma","volume":"21","author":"Rome","year":"2017","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.semcdb.2020.10.006_bb103","first-page":"S63","article-title":"Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24 Suppl 2","author":"Islam","year":"2019","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"key":"10.1016\/j.semcdb.2020.10.006_bb104","first-page":"S52","article-title":"Bortezomib and other proteosome inhibitors-induced peripheral neurotoxicity: from pathogenesis to treatment","volume":"24 Suppl 2","author":"Velasco","year":"2019","journal-title":"J. Peripher. Nerv. Syst. JPNS"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb105","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-0609.2010.01533.x","article-title":"Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib\u2013melphalan\u2013prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study","volume":"86","author":"Dimopoulos","year":"2011","journal-title":"Eur. J. Haematol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb106","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11060-014-1632-x","article-title":"Chemotherapy-induced peripheral neuropathies in hematological malignancies","volume":"121","author":"Jongen","year":"2015","journal-title":"J. Neuro-Oncol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb107","unstructured":"WHO, Guidelines for the Pharmacological and Radiotherapeutic Management of Cancer Pain in Adults and Adolescents, WHO Guidelines Approved by the Guidelines Review Committee, (c) World Health Organization 2018., Geneva, 2018."},{"key":"10.1016\/j.semcdb.2020.10.006_bb108","article-title":"Bisphosphonates in multiple myeloma: an updated network meta-analysis","volume":"12","author":"Mhaskar","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.semcdb.2020.10.006_bb109","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.bone.2015.04.004","article-title":"A review of current murine models of multiple myeloma used to assess the efficacy of therapeutic agents on tumour growth and bone disease","volume":"77","author":"Paton-Hough","year":"2015","journal-title":"Bone"},{"issue":"16","key":"10.1016\/j.semcdb.2020.10.006_bb110","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1200\/JCO.2013.51.7219","article-title":"Pain and nociception: mechanisms of cancer-induced bone pain","volume":"32","author":"Falk","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb111","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1749-6632.2009.05429.x","article-title":"Bone cancer pain","volume":"1198","author":"Jimenez-Andrade","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.semcdb.2020.10.006_bb112","article-title":"Role of the bone microenvironment in the development of painful complications of skeletal metastases","volume":"10","author":"Park","year":"2018"},{"issue":"7","key":"10.1016\/j.semcdb.2020.10.006_bb113","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/01.ajp.0000210902.67849.e6","article-title":"Similarities and differences in tumor growth, skeletal remodeling and pain in an osteolytic and osteoblastic model of bone cancer","volume":"22","author":"Halvorson","year":"2006","journal-title":"Clin. J. Pain"},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb114","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2141.2009.07980.x","article-title":"Myeloma cell\u2010induced disruption of bone remodelling compartments leads to osteolytic lesions and generation of osteoclast\u2010myeloma hybrid cells","volume":"148","author":"Andersen","year":"2010","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb115","article-title":"Acidic microenvironment and bone pain in cancer-colonized bone","volume":"4","author":"Yoneda","year":"2015","journal-title":"Bone Rep."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb116","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00774-006-0734-8","article-title":"Acidic microenvironment created by osteoclasts causes bone pain associated with tumor colonization","volume":"25","author":"Nagae","year":"2007","journal-title":"J. Bone Miner. Metab."},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb117","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1158\/0008-5472.CAN-15-3545","article-title":"Bone pain induced by multiple myeloma is reduced by targeting V-ATPase and ASIC3","volume":"77","author":"Hiasa","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb118","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1038\/s41598-019-41779-w","article-title":"Innervation is higher above bone remodeling surfaces and in cortical pores in human bone: lessons from patients with primary hyperparathyroidism","volume":"9","author":"Sayilekshmy","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2020.10.006_bb119","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuroscience.2011.01.039","article-title":"The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A","volume":"178","author":"Castaneda-Corral","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.semcdb.2020.10.006_bb120","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.neuroscience.2018.01.047","article-title":"The changing sensory and sympathetic innervation of the young, adult and aging mouse femur","volume":"387","author":"Chartier","year":"2018","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb121","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb122","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/ejn.12462","article-title":"The neurobiology of skeletal pain","volume":"39","author":"Mantyh","year":"2014","journal-title":"Eur. J. Neurosci."},{"issue":"6","key":"10.1016\/j.semcdb.2020.10.006_bb123","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jpain.2010.12.016","article-title":"Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers","volume":"12","author":"Bloom","year":"2011","journal-title":"J. Pain"},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb124","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.pain.2011.07.020","article-title":"Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain","volume":"152","author":"Jimenez-Andrade","year":"2011","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb125","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.neuroscience.2010.08.056","article-title":"Blockade of nerve sprouting and neuroma formation markedly attenuates the development of late stage cancer pain","volume":"171","author":"Mantyh","year":"2010","journal-title":"Neuroscience"},{"issue":"9","key":"10.1016\/j.semcdb.2020.10.006_bb126","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1097\/j.pain.0000000000000211","article-title":"Efficacy and safety of tanezumab in the treatment of pain from bone metastases","volume":"156","author":"Sopata","year":"2015","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb127","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.expneurol.2004.11.028","article-title":"Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain","volume":"193","author":"Peters","year":"2005","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb128","doi-asserted-by":"crossref","first-page":"14189","DOI":"10.1038\/s41598-019-50591-5","article-title":"Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment","volume":"9","author":"Olechnowicz","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.semcdb.2020.10.006_bb129","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10252","article-title":"Differential pain-related behaviours and bone disease in immunocompetent mouse models of myeloma","volume":"4","author":"Diaz-delCastillo","year":"2020","journal-title":"JBMR Plus"},{"issue":"1\u20132","key":"10.1016\/j.semcdb.2020.10.006_bb130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3959(96)03267-8","article-title":"Malignant bone pain: pathophysiology and treatment","volume":"69","author":"Mercadante","year":"1997","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb131","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/74999","article-title":"Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord","volume":"6","author":"Honore","year":"2000","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.semcdb.2020.10.006_bb132","doi-asserted-by":"crossref","first-page":"10886","DOI":"10.1523\/JNEUROSCI.19-24-10886.1999","article-title":"Neurochemical and cellular reorganization of the spinal cord in a murine model of bone cancer pain","volume":"19","author":"Schwei","year":"1999","journal-title":"J. Neurosci."},{"key":"10.1016\/j.semcdb.2020.10.006_bb133","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/1742-2094-11-75","article-title":"CXCL12 in astrocytes contributes to bone cancer pain through CXCR4-mediated neuronal sensitization and glial activation in rat spinal cord","volume":"11","author":"Shen","year":"2014","journal-title":"J. Neuroinflamm."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb134","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11596-012-0051-5","article-title":"Inhibition of glial activation in rostral ventromedial medulla attenuates mechanical allodynia in a rat model of cancer-induced bone pain","volume":"32","author":"Liu","year":"2012","journal-title":"J. Huazhong Univ. Sci. Technol. Med. Sci."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb135","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/SPC.0b013e328133f5e9","article-title":"Central neuronal mechanisms in cancer-induced bone pain","volume":"1","author":"Gordon-Williams","year":"2007","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb136","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pain.2003.08.002","article-title":"Alterations in dorsal horn neurones in a rat model of cancer-induced bone pain","volume":"106","author":"Urch","year":"2003","journal-title":"Pain"},{"key":"10.1016\/j.semcdb.2020.10.006_bb137","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2010.03.083","article-title":"Involvement of the spinal NMDA receptor\/PKCgamma signaling pathway in the development of bone cancer pain","volume":"1335","author":"Xiaoping","year":"2010","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.semcdb.2020.10.006_bb138","first-page":"2261","article-title":"Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review","volume":"22","author":"Mols","year":"2014","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.semcdb.2020.10.006_bb139","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.pain.2014.09.020","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny","year":"2014","journal-title":"Pain"},{"issue":"9","key":"10.1016\/j.semcdb.2020.10.006_bb140","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.jpain.2011.04.008","article-title":"Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients","volume":"12","author":"Boyette-Davis","year":"2011","journal-title":"J. Pain"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb141","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3000243","article-title":"Animal models of chemotherapy-induced peripheral neuropathy: a machine-assisted systematic review and meta-analysis","volume":"17","author":"Currie","year":"2019","journal-title":"PLoS Biol."},{"issue":"3","key":"10.1016\/j.semcdb.2020.10.006_bb142","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/hon.2706","article-title":"Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials","volume":"38","author":"Li","year":"2020","journal-title":"Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb143","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.expneurol.2010.02.006","article-title":"Neurophysiological, histological and immunohistochemical characterization of bortezomib-induced neuropathy in mice","volume":"223","author":"Bruna","year":"2010","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb144","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.jphs.2015.08.006","article-title":"Behavioral and pharmacological characteristics of bortezomib-induced peripheral neuropathy in rats","volume":"129","author":"Yamamoto","year":"2015","journal-title":"J. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb145","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ejpain.2009.07.001","article-title":"Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and pathological study in rats","volume":"14","author":"Meregalli","year":"2010","journal-title":"Eur. J. Pain"},{"issue":"1","key":"10.1016\/j.semcdb.2020.10.006_bb146","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.expneurol.2006.11.010","article-title":"Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat","volume":"204","author":"Cavaletti","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.semcdb.2020.10.006_bb147","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neuroscience.2014.11.009","article-title":"Spinal astrocyte gap junction and glutamate transporter expression contributes to a rat model of bortezomib-induced peripheral neuropathy","volume":"285","author":"Robinson","year":"2015","journal-title":"Neuroscience"},{"issue":"5","key":"10.1016\/j.semcdb.2020.10.006_bb148","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcdb.2020.10.006_bb149","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/180428","article-title":"Bortezomib treatment produces nocifensive behavior and changes in the expression of TRPV1, CGRP, and substance P in the rat DRG, spinal cord, and sciatic nerve","volume":"2014","author":"Quartu","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb150","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.expneurol.2012.08.023","article-title":"Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy","volume":"238","author":"Zheng","year":"2012","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.semcdb.2020.10.006_bb151","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s12640-009-9086-1","article-title":"Bortezomib Induces the Formation of Nuclear poly(A) RNA Granules Enriched in Sam68 and PABPN1 in Sensory Ganglia Neurons","volume":"17","author":"Casafont","year":"2009","journal-title":"Neurotox. Res."},{"key":"10.1016\/j.semcdb.2020.10.006_bb152","series-title":"Bortezomib in the Treatment of Multiple Myeloma","first-page":"149","article-title":"Second-Generation Proteasome Inhibitors","author":"Esseltine","year":"2011"},{"issue":"4","key":"10.1016\/j.semcdb.2020.10.006_bb153","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1600-0609.2012.01831.x","article-title":"Health-related quality of life and disease-specific complaints among multiple myeloma patients up to 10 yr after diagnosis: results from a population-based study using the PROFILES registry","volume":"89","author":"Mols","year":"2012","journal-title":"Eur. J. Haematol."},{"issue":"11","key":"10.1016\/j.semcdb.2020.10.006_bb154","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.ejca.2007.04.022","article-title":"An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma","volume":"43","author":"Cocks","year":"2007","journal-title":"Eur. J. Cancer"}],"container-title":["Seminars in Cell & Developmental Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952120300148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1084952120300148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T17:00:13Z","timestamp":1761066013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1084952120300148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":154,"alternative-id":["S1084952120300148"],"URL":"https:\/\/doi.org\/10.1016\/j.semcdb.2020.10.006","relation":{},"ISSN":["1084-9521"],"issn-type":[{"value":"1084-9521","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple myeloma\u2014A painful disease of the bone marrow","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cell & Developmental Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcdb.2020.10.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}